New drug trial aims to halt scarring in rare blood vessel disease
NCT ID NCT07325357
Summary
This study is testing if adding the drug pirfenidone to standard treatment can better control Takayasu arteritis, a rare disease that causes scarring and narrowing of blood vessels. Researchers will compare pirfenidone to a placebo in 92 patients already on standard therapy to see if it reduces vessel wall thickening and improves patient outcomes. The goal is to directly target the scarring process that current treatments often fail to stop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.